On 19 February 2026, Zydus announced the Indian launch of Anyra™, biosimilar to Regeneron/Bayer’s Eylea® (aflibercept) 2 mg. Anyra™ is the first aflibercept 2mg biosimilar developed in India and is launched under licence from Regeneron and Bayer.
Anyra™ is approved for the treatment of wet age-related macular degeneration, diabetic retinopathy, visual impairment due to macular oedema following retinal vein occulsion, diabetic macular oedema and myopic choroidal neovascularisation.
Zydus’ Indian developed and manufactured biosimilar portfolio includes more than 13 biosimilars and complex biologics.
There is at least one other aflibercept biosimilar set to launch in India in 2026. In September 2025, Biocon’s Yesafili®, biosimilar to Regeneron/Bayer’s Eylea® (aflibercept) 2mg, was recommended by India’s Subject Expert Committee (SEC). This recommendation was subject to Biocon submitting a Phase IV clinical trial protocol to the CDSC within 3 months of obtaining the marketing authorisation grant. In January 2026, Biocon Biologics reached a settlement and licence agreement with Regeneron and Bayer for Yesafili® in Europe and ROW, which permits Biocon to commercialise Yesafili® in India (and ROW other than UK, US and Canada) in H2 2026.